Adult Molecular Tumor Board

Target Audience  

Neuro-oncologists, medical oncologists, neurosurgeons, neurologists, radiation oncologists, radiologists, neuropathologists, physicians/scientists, clinical and laboratory trainees, and allied health professionals. 

Statement of Need/Program Overview   

CNS lymphoma represents a rare but aggressive malignancy for which treatment outcomes remain suboptimal, particularly in elderly patients and those with secondary CNS involvement. The emergence of BTK inhibitors and CAR-T cell and cellular therapies offers transformative potential, but clinicians require updated guidance on integrating these agents into practice. This SNO Adult Molecular Tumor Board will convene leading experts to review primary and secondary CNS lymphoma, discuss cutting-edge therapies, and offer perspectives on the future of clinical trial design in this evolving landscape. 

Educational Objectives  

After participating in this CME activity, participants should be able to:   

• Distinguish primary from secondary CNS lymphoma and apply current molecular classification systems to guide diagnosis and management. 
• Evaluate the clinical evidence for novel therapies including BTK inhibitors, CAR-T cell therapy, and other cellular therapies in CNS lymphoma, including mechanisms, efficacy, and toxicity. 
• Discuss how molecular profiling has shifted the diagnostic and therapeutic paradigm, and identify genomic alterations relevant to patient management. 

Physician Accreditation Statement  

The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Credit Designation 
The Society for Neuro-Oncology designates this live activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure of Relevant Financial Relationships   

The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. To view the disclosure list, please click here.

Disclosure of Unlabeled Use  

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer  

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

SNO CME Contact Information 

For more information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, Buchanan, RN at melesa@soc-neuro-onc.org